Description
Bristol-Myers Squibb: Will The Enhanced Focus on Cell Therapy and Innovative Cancer Treatments Pay Off?
Bristol-Myers Squibb reported its second quarter 2024 earnings showcasing continued execution of its long-term strategy aimed at fostering sustainable growth. The company highlighted an 18% year[1]over-year increase in its growth portfolio revenues, amounting to a 21% rise when excluding the impact of foreign exchange. This bolstered growth originated largely from several marketed products gaining traction in the market.
Our Report Structure:
⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures
Want unlimited access to our reports? Purchase our $99 annual subscription!
